The study of the physico-chemical properties of the substance darunavir ethanolate


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The aim of the work was to study the physicochemical properties of darunavir ethanolate for the development of a scheme for the synthesis of a pharmaceutical substance and the creation of a domestic innovative dosage form. The following methods were used: differential scanning calorimetry, potentiometric titration, highly efficient liquid chromatography, capillary method for determining the melting point. The following parameters were determined: melting point, solubility in aqueous solutions and organic solvents, distribution coefficient, apparent distribution coefficient and dissociation constant. It is established that the substance is poorly soluble in aqueous solutions in the pH range from 1 to 12, soluble in a number of organic solvents. The distribution coefficient in the solvent system octanol 1 / phosphate buffer solution pH 7.0 was 292, the apparent distribution coefficient in the solvent system octanol / 0.1 N hydrochloric acid solution - 30.9. The dissociation constant was 2.02, the melting point is in the range from 74 to 78 °C. The obtained results were processed using Microsoft Office Excel 2016 software in MS Windows 7 environment. It was experimentally shown that the substance of darunavir ethanolate is lipophilic, the main site of its absorption by oral administration will be the intestine. To increase the effectiveness of the substance, the application of technologies aimed at increasing the solubility in aqueous media is promising. The article presents the results of the study of the physicochemical properties of the substance darunavir ethanolate antiretroviral action.

Full Text

Restricted Access

About the authors

S. A Zolotov

LLC «AMEDART»

Email: duim50@gmail.com
Director for the Production and Development of Drugs and Active Pharmaceutical Substances Moscow

N. B Demina

Sechenov First Moscow State Medical University

Email: nbd217@mail.ru
Dr.Sc. (Pharm.), Professor, Department of Pharmaceutical Technology Institute of Pharmacy Moscow

A. S Zolotova

LLC «Farm-Sintez Lab»

Email: max_in_a@mail.ru
Ph.D. (Pharm.), Head of the Laboratory of Drug Technology Moscow

References

  1. EMA/669488/2014 Corr. 1 Committee for Medicinal Products for Human Use (CHMP) Assessment report Rezolsta International non-proprietary name: darunavir/ cobicistat Procedure No. EMEA/H/C/002819/0000 September 2014.
  2. ICH Q8(R2). PHARMACEUTICAL DEVELOPMENT // Current Step 4 version.- August 2009.
  3. Dr. Fei Mao, Qingya Kong, Wei Ni, Xiang Xu, Dazheng Ling, Zhengyu Lu, Prof. Jian Li. Melting Point Distribution Analysis of Globally Approved and Discontinued Drugs: A Re search for Improving the Chance of Success of Drug Design and Discovery // Chemistry Open. 2016 Aug; 5(4): 357-368.
  4. Reddy B.V., Jyothi G., Reddy B.S., Raman N.V., Reddy K.S., Rambabu C. Stability-indicating HPLC method for the determination of darunavir ethanolate // 2013 May-Jun; 51(5):471-476.
  5. Демина Н.Б. Биофармацевтическая классификационная система как инструмент разработки дизайна и технологии лекарственной формы // Разработка и регистрация лекарственных средств. 2017. № 2. С. 12-17.
  6. Chaves Ruela Correa J., D ’Arcy D.M., dos Reis C.H., Nunes Salgado S.H.R. Darunavir: A Critical review of its properties, use and drug interactions // Pharmacology. 2012; 90:102-109.
  7. Решение Совета Евразийской экономической комиссии от 03.11.2016 N 78 (ред. от 14.06.2018) «О Правилах регистрации и экспертизы лекарственных средств для медицинского применения». Приложение № 14 с. 10
  8. Альберт А. Избирательная токсичность. Физико-химические основы терапии / Пер. с англ. В 2 томах. Т. 2. М.: Медицина, 1989. 432 с.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies